Articles Mentioning Defensive Stocks

Results 1 - 10 of 123 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Defensive

Investing | April 25, 2015

3 Best Stocks for Investing in Generic Drugs

The generic-drug market is sizzling hot. Here are three investing ideas to catch some of that heat wave.

Investing | April 05, 2015

Can This Pharma Go From Good to Great?

Will Actavis' $66 billion merger with Allergan catapult this company from good to great? Or could a hidden risk derail this global powerhouse?

Investing | February 01, 2015

The Top Healthcare Stock to Buy in February

3 Motley Fool contributors share their top picks for February.

Investing | January 31, 2015

Big Pharma: An Up-Close Look at One Key Player

Industry Focus zooms in on restructuring, new drugs, and possible threats for pharma giant Novartis.

Investing | December 19, 2014

The Best Healthcare Stocks of 2014: Which Is Our Favorite for 2015?

In this week's Industry Focus, our analysts discuss their favorites of the successful 2014 healthcare large-cap stocks.

Investing | December 08, 2014

Is It Time to Buy This Growth Stock?

Specialty and generic drugmaker Actavis has been going through a rapid growth spurt, spurred by its numerous acquisitions. After completing a mega merger with Botox-maker Allergan, can the uptrend continue?

Investing | December 07, 2014

The 3 Most Memorable Moments in Healthcare This Year

Three Motley Fool analysts tell investors what they believe are the year's most memorable events in the healthcare sector.

Investing | November 25, 2014

Should Allergan Investors Stick With Actavis?

Just because you own Allergan doesn't mean you should necessarily own Actavis.

Investing | November 12, 2014

5 Things Actavis plc's Management Wants You to Know

Specialty and generic drugmaker Actavis plc reported another monster quarter last week. Here are five things management wants investors to know going forward.

Investing | November 11, 2014

Bill Ackman vs. Allergan, Inc.: Who Will Win the War of Words?

Valeant Pharmaceuticals' takeover bid for Allergan has turned hostile in more ways than one.

Results 1 - 10 of 123 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Defensive